The use of Cilostazol in Diabetic Patients
The International Diabetes Federation (IDF) reported that the global prevalence of diabetes (DM) in adults was 8.3% in 2013 expecting to rise beyond 592 million by 2035 with a 10.1% global prevalence [1]. Guidelines have been published for the treatment of this major disease and its complications [2...
Gorde:
Egile Nagusiak: | Konstantinos Spanos (Egilea), Athanasios D Giannoukas (Egilea) |
---|---|
Formatua: | Liburua |
Argitaratua: |
International Journal of Vascular Surgery and Medicine - Peertechz Publications,
2016-09-20.
|
Gaiak: | |
Sarrera elektronikoa: | Connect to this object online. |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Antzeko izenburuak
-
Pharmacological Potential of Cilostazol for Alzheimer's Disease
nork: Kenjiro Ono, et al.
Argitaratua: (2019) -
Determination of cilostazol and its active metabolite 3,4-dehydro cilostazol from small plasma volume by UPLCâMS/MS
nork: Nejal M. Bhatt, et al.
Argitaratua: (2015) -
Cilostazol Ameliorates Peripheral Neuropathic Pain in Streptozotocin-Induced Type I Diabetic Rats
nork: Kuang-I. Cheng, et al.
Argitaratua: (2022) -
Risk of Heart Failure Hospitalization Associated With Cilostazol in Diabetes: A Nationwide Case-Crossover Study
nork: Cho-Kai Wu, et al.
Argitaratua: (2019) -
THE LEVEL OF SEROTONIN IN PATIENTS WITH GENERALIZED ATHEROSCLEROSIS AND ITS DYNAMICS UNDER THE INFLUENCE OF CILOSTAZOL
nork: Tatiana Motsak, et al.
Argitaratua: (2020)